Alteration in adenosine monophosphate deaminase activity and ferric reducing capacity in diabetic renal failure patients.

Renal failure is the final stage of chronic kidney disease (a common complication of diabetic mellitus) usually occurs due to delayed treatment or poor disease control with Glomerular filtration Rate falling below 15 mL/min leading to severe deterioration of renal function. Meanwhile Adenosine Monophosphate Deaminase (AMPD) participate in purine metabolism; affecting energy balance.The aim of this study was to investigate the diagnostic significance of AMPD activity with some parameters including ferric reducing capacity (FRC) as an indicator of oxidative stress.The participants of the work divided into: healthy Subject (H), renal failure patients (RF) and renal failure with diabetes mellitus (RF + DM). The results showed a significant increase in AMPD activity in diabetic RF group than RF group without (25.57 ± 3.06 and 16.30 ± 3.44) as well as when compared with healthy subjects (5.89 ± 1.59), levels of FRC were increased also especially in the RF + DM indicating a compensatory increase in antioxidant capacity in response to oxidative stress that caused from RF and DM. Cluster analysis reveals systematic signature in RF where most parameters are closely correlated identifying sensitive indicators of renal health while FRC demonstrate an independent outlier from traditional filtration metrics. ROC curve showed that both markers had excellent diagnostic accuracy with (AUC = 0.9) indicating that they are strong and early biomarkers for RF particularly in diabetic patients. The findings also suggest that inhibition of AMPD activity may help improve metabolism, reduce inflammation, and oxidative stress leading to providing vital protection against RF.